Jason, to briefly. joining of I'll but recent like with some of them through you this many already these, thanks, for of Thanks, start highlights, most that I'd afternoon. are everyone, very run and aware
for Of ADHD was approved milestone AZSTARYS, back a of launched XXst, are in commercially our course, us. most product aware exciting that very March, you lead that was on July
at that progresses. extent as of update, XXXX expect time. further announced launch in any you'll probably excited do that see and can We that Corium, is we the in partner, how see are that hear Our But give projections sales sort royalties this we to beyond. and milestones of and to
until single the rates recall, the XXXX. may sales up run our the mid to you digits US AZSTARYS from on patents And as Just royalty go XXs. high
XX us product here opportunity AZSTARYS. in front a we just of in with now for year a life sitting have launched, that XXXX product just a tremendous So
as notice received is LaDuane has All take products beneficial. methylphenidate means the the containing controlled for products in all only Schedule second III that a to recommendation it happy heard from product for when as also is that our Schedule the This to quarter, based be FDA it's right other Scheduled a compared key Serdexmethylphenidate, remarkably us did It great a and candidates. substance. the lower and I'd We differentiator fact, IV. It is II. value the in a key and, for or also IV only DEA are give SDX, potential now product Not methylphenidate it's than SDX abuse d-methylpenidate AZSTARYS. will product, a details. Schedule a lower that, report other to proposition schedule
sheet. We have a healthy balance
have net income. We also
he'll shortly. to So get about talk that
that clinical just our the some in Tech and different care beyond about future, from the us. expanding in holds and a perspectives a more which And collaboration moment. explain known have expect more we excited SDX. year-end ongoing. course, that's not that's do avenues warrant It's in Of as combination know that received regulatory I same especially the word second additional we as the to for of SDX will to hear regions. I expand time, have was still transaction, he'll potential. the rolling royalties But sales many mouth certainly, anymore, APADAZ. They're That the to detail pass And but milestones detail then did Med are think great you for at very collaboration often prior is Sure the into as something AZSTARYS. data that well to along in KVK preparing that quarter. with they're to
us. to any be they hear to we'll updates that along passed excited about So
moving So on.
is well AZSTARYS As launch I mentioned, extensively, underway. the of commercial US
We the so product, Corium. are about excited as
have please you chance, website. If the visit a
also undertaking product, to You tactics the of promotional and can label sales Corium that differentiation the the based related product, primarily for AZSTARYS. some all more learn is about around the
those is with or meaningful. or include administered. the height is and remember water. over how label you be product various very changes clinically opened It no of taken The product that sprinkled apple could the sauce recall, It elements without pharmacokinetics be weight was can time on There smooth. and or if were in So up food. in
and long morning decrease entirety a data We have the efficacy the an early throughout the gradually And onset of this show in peak day. very to does early that, the duration early day. then you through tends have through the it that
instances, All had substance, different makes of we about completely control what a road. commercialization product along. to In will pass is this that, it mentioned, very IV a be available which that SDX, as Corium and today. type is is combined provide with I us everyone this particular a when XX% did talk early days. some product Control slow of going will we're updates the also, this really those caution methylphenidate fact I that
have And of We industry that a It's period these actually with for payers select about by initially a payers from I coverage states that's and you to see seen in that's many six products believe be few time fact number types to block wide large initially of will payer have focused going really just reimbursed launch. patient standards. in due being launch all as to of a the will of different a how lot mainly, to be prescribers. a around cases, don't factors. And month
for the to blood that be a payer something block AZSTARYS, until need NDC company it and So or discuss it's initial see any to has of new placed review a it. chance product. or with contracts front matter potential going it's It that for oncology, in pressure, didn't any something to if
opens payer worried to like that a to environment to is feedback, starting become that they COVID a We opens contracting write payer amount they're Corium And the initial just initial of pay that up hear we indicated think that are when product. will Many that and strategy. perfect up, have And heard from national to sales the you filled, It access scripts Don't of this get get to current the well launch I for as would some velocity payers AZSTARYS, have launch differentiation. discuss side. as oversell because from given folks. have they're get when large some physicians stopped a heard have receptivity with will payers the that some expand. a going when more then its times, Don't that it. have bunch at don't actually Corium
know certainly exactly So doing. they're they what
resources them see we are excited and this to forward. all have they in think the place take I
may for internal April. you label, did we be amendment really did this back the license As of basis update aware, the to GPC our agreement And we affiliate COMAV, in that was the with which based an that on is forecast.
SDX it's Moving number opportunity. us scheduling. serdex, of or opportunity. there's on unique the and the different I've the about Certainly, and the pure of But to features CX here, real a briefly prodrug on provides profile also a on rattled that
molecule. unique pharmacokinetic as can't for So fact methylphenidates you us in the chance well abuseability a really to swap that just on profile. as the And other capitalize this it have you gives this lower potential
that product us for so trial was with good it lot IND. tell initiated XXX than reason And a is study SDX stimulant use KPXXX more so designed the this very did could SDX. calling recently disorder. for I'm to about just We we do itself a this what a under a not
safety effects. some So well we're of the as exploring exploratory as the pharmacokinetics and at high doses
related effects side come like be wakefulness effects to would this side may that So methylphenidate abuseability the product. and/or with
trial to from quarter really year It's abuse, next haven't to the that. we in. do be believe stimulant to of for why everything to year year a sort it. study, or can't with point reason it's exactly almost stimulant use going at history looking tell prior end. announced enroll people it's heard the of significant somewhere between of third it’s of difficult really the going of you We're the quarter be We because -- some last this I going a to primarily addiction. And to year initiation and when I first
And clinical same it to individuals pick that we going We're where most right the what disorder? keep idiopathic number the molecule. a best we other study as Is announced has decide for to and one bit opportunity that to the used they're perspective. you to reliable the that won't the well, do stimulant to not others? primarily little be itself it the the as XXXX do that that last to going is with one There's going or which to program. Is product potential for need from so We future those too well year as right really data cannibalize product conditions indications. use want much market the of use be individuals, the the from for can a in a different hypersomnia,
So through financial turn now to that over with that, LaDuane? I I'm going a run to update. it you provide LaDuane to
